个人中心 - 老虎社区

Hoekee

IP属地：未知

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- HoekeeHoekee
  ·2021-01-28
  Good
  空头依然在！即便暴涨10倍，GME的逼空故事还远未结束
  在遭到散户多头的疯狂狙击后，GME在一个月内暴涨十倍，美国百亿对冲基金Melvin Capital已平仓对GME的空头头寸，而其他空头机构也战战兢兢，试图减少空单风险敞口，避免重蹈覆辙。即便如此，在
  空头依然在！即便暴涨10倍，GME的逼空故事还远未结束
  130 评论
  点赞
  分享
  举报
- HoekeeHoekee
  ·2021-01-27
  [龇牙]
  贝康医疗-B今起招股，入场费约13817.85港元
  1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预
  贝康医疗-B今起招股，入场费约13817.85港元
  527 评论
  点赞
  分享
  举报
- HoekeeHoekee
  ·2021-01-23
  [微笑]
  非常抱歉，此主贴已删除
  558 评论
  点赞
  分享
  举报
- HoekeeHoekee
  ·2021-01-23
  [微笑] [微笑]
  哔哩哔哩涨近6%，传其港股将于三月初开始招股
  1月22日，哔哩哔哩盘中涨近6%，传其港股将于三月初开始招股。B站已于1月第二周在港正式提交了上市申请。B站上市团队希望3月在港敲钟上市，但是其具体的时间表仍需要根据港交所过聆讯的时间来安排。
  哔哩哔哩涨近6%，传其港股将于三月初开始招股
  811 评论
  点赞
  分享
  举报
暂无关注

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3569733015993829","uuid":"3569733015993829","gmtCreate":1606648915258,"gmtModify":1611334434375,"name":"Hoekee","pinyin":"hoekee","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/db64510f3081f6db5b05e8e85ca1a23e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":17,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.97%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":311799753,"gmtCreate":1611829326272,"gmtModify":1703754380963,"author":{"id":"3569733015993829","authorId":"3569733015993829","name":"Hoekee","avatar":"https://static.tigerbbs.com/db64510f3081f6db5b05e8e85ca1a23e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569733015993829","authorIdStr":"3569733015993829"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311799753","repostId":"2106500612","repostType":4,"repost":{"id":"2106500612","pubTimestamp":1611829082,"share":"https://www.laohu8.com/m/news/2106500612?lang=&edition=full","pubTime":"2021-01-28 18:18","market":"us","language":"zh","title":"空头依然在！即便暴涨10倍，GME的逼空故事还远未结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2106500612","media":"华尔街见闻","summary":"在遭到散户多头的疯狂狙击后，GME在一个月内暴涨十倍，美国百亿对冲基金Melvin Capital已平仓对GME的空头头寸，而其他空头机构也战战兢兢，试图减少空单风险敞口，避免重蹈覆辙。\n即便如此，在","content":"<p>在遭到散户多头的疯狂狙击后，GME在一个月内暴涨十倍，美国百亿对冲基金Melvin Capital已平仓对GME的空头头寸，而其他空头机构也战战兢兢，试图减少空单风险敞口，避免重蹈覆辙。</p>\n<p>即便如此，在美国市场上试图做空GME的机构依然络绎不绝。目前S3 Partners负责人Ihor Dusaniwsky负责提供实时的每日空头头寸跟踪，<b>他表示目前被做空的流通股比例仍然达到了139.7％，已经逼近月初的高位。</b></p>\n<p><img src=\"https://static.tigerbbs.com/81f3c85ba2330ba3cd5d73186d9d2561\" tg-width=\"575\" tg-height=\"344\" referrerpolicy=\"no-referrer\"></p>\n<p>更令人惊讶的是，在本周早些时候，GME短期融券费用达到了惊人的30.6％。</p>\n<p><img src=\"https://static.tigerbbs.com/40873fb62f84833c90284086b8b8ee20\" tg-width=\"500\" tg-height=\"363\" referrerpolicy=\"no-referrer\"></p>\n<p>根据Dusaniwsky的说法，此费用已飙升至100％，有时甚至高达250％，即便是现有空头，仍然需要支付30-50％的融券成本，空头做空的成本十分惊人。高额的融券费用只会加剧导致空头爆仓。</p>\n<p>而且，尽管融券费用暴涨，但GME的空头头寸却在增加。如果站在多方角度来看，真正的逼空还未开始。</p>","source":"wallstreetcn_api","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>空头依然在！即便暴涨10倍，GME的逼空故事还远未结束 </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n空头依然在！即便暴涨10倍，GME的逼空故事还远未结束 \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-28 18:18 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3618764><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在遭到散户多头的疯狂狙击后，GME在一个月内暴涨十倍，美国百亿对冲基金Melvin Capital已平仓对GME的空头头寸，而其他空头机构也战战兢兢，试图减少空单风险敞口，避免重蹈覆辙。\n即便如此，在美国市场上试图做空GME的机构依然络绎不绝。目前S3 Partners负责人Ihor Dusaniwsky负责提供实时的每日空头头寸跟踪，他表示目前被做空的流通股比例仍然达到了139.7％，已经逼近...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3618764\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/7d7c9c3f45a3fb186bb48dc3d3495c59","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://wallstreetcn.com/articles/3618764","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2106500612","content_text":"在遭到散户多头的疯狂狙击后，GME在一个月内暴涨十倍，美国百亿对冲基金Melvin Capital已平仓对GME的空头头寸，而其他空头机构也战战兢兢，试图减少空单风险敞口，避免重蹈覆辙。\n即便如此，在美国市场上试图做空GME的机构依然络绎不绝。目前S3 Partners负责人Ihor Dusaniwsky负责提供实时的每日空头头寸跟踪，他表示目前被做空的流通股比例仍然达到了139.7％，已经逼近月初的高位。\n\n更令人惊讶的是，在本周早些时候，GME短期融券费用达到了惊人的30.6％。\n\n根据Dusaniwsky的说法，此费用已飙升至100％，有时甚至高达250％，即便是现有空头，仍然需要支付30-50％的融券成本，空头做空的成本十分惊人。高额的融券费用只会加剧导致空头爆仓。\n而且，尽管融券费用暴涨，但GME的空头头寸却在增加。如果站在多方角度来看，真正的逼空还未开始。","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313615109,"gmtCreate":1611707847401,"gmtModify":1703752493659,"author":{"id":"3569733015993829","authorId":"3569733015993829","name":"Hoekee","avatar":"https://static.tigerbbs.com/db64510f3081f6db5b05e8e85ca1a23e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569733015993829","authorIdStr":"3569733015993829"},"themes":[],"htmlText":"[龇牙]&nbsp;","listText":"[龇牙]&nbsp;","text":"[龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/313615109","repostId":"1148412616","repostType":4,"repost":{"id":"1148412616","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611707484,"share":"https://www.laohu8.com/m/news/1148412616?lang=&edition=full","pubTime":"2021-01-27 08:31","market":"hk","language":"zh","title":"贝康医疗-B今起招股，入场费约13817.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148412616","media":"老虎资讯综合","summary":"1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预","content":"<p>1月27日，<a href=\"https://laohu8.com/S/02170\">贝康医疗-B</a>发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预期将于2月8日上市。</p><p><img src=\"https://static.tigerbbs.com/e70b9d2ed54bdbb42ae460c33ba54400\" tg-width=\"659\" tg-height=\"641\" referrerpolicy=\"no-referrer\"></p><p><b>申购阶梯：</b></p><p>甲组每手500股，入场费约13817.85港元。</p><p>乙组头为20万股，申购所需资金约5527141.34港元。</p><p><img src=\"https://static.tigerbbs.com/4a2a3c6a0dca8a1c930651ef589ee5e4\" tg-width=\"1133\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>据悉，贝康医疗是中国辅助生殖基因检测解决方案的创新平台， 目前公司已经将涉猎范围从植入前阶段扩展至产前和产后阶段，并且正在每个阶段开发一个试剂盒，这使其成为基因检测试剂盒产品线覆蓋整个生殖周期的中国公司。</p><p>公司的产品PGT-A试剂盒可以在植入前筛查胚胎中的非整倍体（一种经常与试管婴儿(IVF)植入失败相关的染色体疾病），是首个也是唯一已获国家药监局批准的三代试管婴儿基因检测试剂盒，该试剂盒于2020年2月作为三类「创新医疗器械」获国家药监局注册，标志着中国受监管的三代试管婴儿市场的诞生，而公司是迄今唯一获批的试剂盒生产商。</p><p>财务数据方面，于往绩记录期间，公司收入主要来自于自主开发用于科学研究的基因检测试剂盒的有限销售，以及分销及销售其他厂商生产的检测试剂盒、设备和仪器，尚未盈利，并产生亏损净额。2018财年至2019财年公司总营收分别为人民币3260.9万元及5568.5万元，同比增长70.77%；同期录得净亏损1.57亿元及5.34亿元。2020年前9个月，公司录得总营收5724.3万元，同比增长36.74%，录得净亏损8.52亿元。</p><p><img src=\"https://static.tigerbbs.com/35761150265524efeb53049d99399a21\" tg-width=\"570\" tg-height=\"793\" referrerpolicy=\"no-referrer\"></p><p>行业方面，中国生殖遗传学医疗器械市场相对而言属新兴市场且正在快速发展。受不孕率日益上升、对辅助生殖治疗（如试管婴儿）的需求不断增长、中国健康意识日益提升、基因检测的可购性和可用性不断增加以及技术进步所驱动，中国生殖遗传学医疗器械市场（按基于出厂价计算的销售收入计）已从2015年的人民币13亿元增长至2019年的人民币34亿元，复合年增长率为28.4%，并预期于2024年达到人民币112亿元，2019年至2024年的复合年增长率为26.5%。</p><p>基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约6.98亿港元，包括OrbiMed Funds、清池资本(Lake Bleu Prime )、CRF、AHAM、 WinTwin、Foresight Funds 及IvyRock Fund。</p><p><img src=\"https://static.tigerbbs.com/4781c23410dda3308f5173dc9a41ab5c\" tg-width=\"766\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p>筹资用途方面，公司拟将股份发售所得款项净额用于以下用途：约30%将分配予核心产品PGT-A试剂盒；约20%将用于PGT-M试剂盒的临床试验、注册申报及商业化；约30%将分配用于我们其他产品的开发、临床试验及注册申报；约10%将用于提高研发能力及提升技术；约10%将用作营运资本及一般企业用途。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贝康医疗-B今起招股，入场费约13817.85港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贝康医疗-B今起招股，入场费约13817.85港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-01-27 08:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>1月27日，<a href=\"https://laohu8.com/S/02170\">贝康医疗-B</a>发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预期将于2月8日上市。</p><p><img src=\"https://static.tigerbbs.com/e70b9d2ed54bdbb42ae460c33ba54400\" tg-width=\"659\" tg-height=\"641\" referrerpolicy=\"no-referrer\"></p><p><b>申购阶梯：</b></p><p>甲组每手500股，入场费约13817.85港元。</p><p>乙组头为20万股，申购所需资金约5527141.34港元。</p><p><img src=\"https://static.tigerbbs.com/4a2a3c6a0dca8a1c930651ef589ee5e4\" tg-width=\"1133\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>据悉，贝康医疗是中国辅助生殖基因检测解决方案的创新平台， 目前公司已经将涉猎范围从植入前阶段扩展至产前和产后阶段，并且正在每个阶段开发一个试剂盒，这使其成为基因检测试剂盒产品线覆蓋整个生殖周期的中国公司。</p><p>公司的产品PGT-A试剂盒可以在植入前筛查胚胎中的非整倍体（一种经常与试管婴儿(IVF)植入失败相关的染色体疾病），是首个也是唯一已获国家药监局批准的三代试管婴儿基因检测试剂盒，该试剂盒于2020年2月作为三类「创新医疗器械」获国家药监局注册，标志着中国受监管的三代试管婴儿市场的诞生，而公司是迄今唯一获批的试剂盒生产商。</p><p>财务数据方面，于往绩记录期间，公司收入主要来自于自主开发用于科学研究的基因检测试剂盒的有限销售，以及分销及销售其他厂商生产的检测试剂盒、设备和仪器，尚未盈利，并产生亏损净额。2018财年至2019财年公司总营收分别为人民币3260.9万元及5568.5万元，同比增长70.77%；同期录得净亏损1.57亿元及5.34亿元。2020年前9个月，公司录得总营收5724.3万元，同比增长36.74%，录得净亏损8.52亿元。</p><p><img src=\"https://static.tigerbbs.com/35761150265524efeb53049d99399a21\" tg-width=\"570\" tg-height=\"793\" referrerpolicy=\"no-referrer\"></p><p>行业方面，中国生殖遗传学医疗器械市场相对而言属新兴市场且正在快速发展。受不孕率日益上升、对辅助生殖治疗（如试管婴儿）的需求不断增长、中国健康意识日益提升、基因检测的可购性和可用性不断增加以及技术进步所驱动，中国生殖遗传学医疗器械市场（按基于出厂价计算的销售收入计）已从2015年的人民币13亿元增长至2019年的人民币34亿元，复合年增长率为28.4%，并预期于2024年达到人民币112亿元，2019年至2024年的复合年增长率为26.5%。</p><p>基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约6.98亿港元，包括OrbiMed Funds、清池资本(Lake Bleu Prime )、CRF、AHAM、 WinTwin、Foresight Funds 及IvyRock Fund。</p><p><img src=\"https://static.tigerbbs.com/4781c23410dda3308f5173dc9a41ab5c\" tg-width=\"766\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p>筹资用途方面，公司拟将股份发售所得款项净额用于以下用途：约30%将分配予核心产品PGT-A试剂盒；约20%将用于PGT-M试剂盒的临床试验、注册申报及商业化；约30%将分配用于我们其他产品的开发、临床试验及注册申报；约10%将用于提高研发能力及提升技术；约10%将用作营运资本及一般企业用途。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"02170":"贝康医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148412616","content_text":"1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预期将于2月8日上市。申购阶梯：甲组每手500股，入场费约13817.85港元。乙组头为20万股，申购所需资金约5527141.34港元。据悉，贝康医疗是中国辅助生殖基因检测解决方案的创新平台， 目前公司已经将涉猎范围从植入前阶段扩展至产前和产后阶段，并且正在每个阶段开发一个试剂盒，这使其成为基因检测试剂盒产品线覆蓋整个生殖周期的中国公司。公司的产品PGT-A试剂盒可以在植入前筛查胚胎中的非整倍体（一种经常与试管婴儿(IVF)植入失败相关的染色体疾病），是首个也是唯一已获国家药监局批准的三代试管婴儿基因检测试剂盒，该试剂盒于2020年2月作为三类「创新医疗器械」获国家药监局注册，标志着中国受监管的三代试管婴儿市场的诞生，而公司是迄今唯一获批的试剂盒生产商。财务数据方面，于往绩记录期间，公司收入主要来自于自主开发用于科学研究的基因检测试剂盒的有限销售，以及分销及销售其他厂商生产的检测试剂盒、设备和仪器，尚未盈利，并产生亏损净额。2018财年至2019财年公司总营收分别为人民币3260.9万元及5568.5万元，同比增长70.77%；同期录得净亏损1.57亿元及5.34亿元。2020年前9个月，公司录得总营收5724.3万元，同比增长36.74%，录得净亏损8.52亿元。行业方面，中国生殖遗传学医疗器械市场相对而言属新兴市场且正在快速发展。受不孕率日益上升、对辅助生殖治疗（如试管婴儿）的需求不断增长、中国健康意识日益提升、基因检测的可购性和可用性不断增加以及技术进步所驱动，中国生殖遗传学医疗器械市场（按基于出厂价计算的销售收入计）已从2015年的人民币13亿元增长至2019年的人民币34亿元，复合年增长率为28.4%，并预期于2024年达到人民币112亿元，2019年至2024年的复合年增长率为26.5%。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约6.98亿港元，包括OrbiMed Funds、清池资本(Lake Bleu Prime )、CRF、AHAM、 WinTwin、Foresight Funds 及IvyRock Fund。筹资用途方面，公司拟将股份发售所得款项净额用于以下用途：约30%将分配予核心产品PGT-A试剂盒；约20%将用于PGT-M试剂盒的临床试验、注册申报及商业化；约30%将分配用于我们其他产品的开发、临床试验及注册申报；约10%将用于提高研发能力及提升技术；约10%将用作营运资本及一般企业用途。","news_type":1},"isVote":1,"tweetType":1,"viewCount":527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":310561156,"gmtCreate":1611333305275,"gmtModify":1703750014535,"author":{"id":"3569733015993829","authorId":"3569733015993829","name":"Hoekee","avatar":"https://static.tigerbbs.com/db64510f3081f6db5b05e8e85ca1a23e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569733015993829","authorIdStr":"3569733015993829"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/310561156","repostId":"2105467504","repostType":4,"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":310569006,"gmtCreate":1611333214705,"gmtModify":1703750011244,"author":{"id":"3569733015993829","authorId":"3569733015993829","name":"Hoekee","avatar":"https://static.tigerbbs.com/db64510f3081f6db5b05e8e85ca1a23e","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569733015993829","authorIdStr":"3569733015993829"},"themes":[],"htmlText":"[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/310569006","repostId":"1157177739","repostType":4,"repost":{"id":"1157177739","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611331121,"share":"https://www.laohu8.com/m/news/1157177739?lang=&edition=full","pubTime":"2021-01-22 23:58","market":"us","language":"zh","title":"哔哩哔哩涨近6%，传其港股将于三月初开始招股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157177739","media":"老虎资讯综合","summary":"1月22日，哔哩哔哩盘中涨近6%，传其港股将于三月初开始招股。B站已于1月第二周在港正式提交了上市申请。B站上市团队希望3月在港敲钟上市，但是其具体的时间表仍需要根据港交所过聆讯的时间来安排。","content":"<p>1月22日，哔哩哔哩盘中涨近6%，传其港股将于三月初开始招股。</p><p>B站已于1月第二周在港正式提交了上市申请。B站上市团队希望3月在港敲钟上市，但是其具体的时间表仍需要根据港交所过聆讯的时间来安排。</p><p><img src=\"https://static.tigerbbs.com/a5f9a9adfee07fed56eed89baab74bfb\" tg-width=\"840\" tg-height=\"470\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>哔哩哔哩涨近6%，传其港股将于三月初开始招股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n哔哩哔哩涨近6%，传其港股将于三月初开始招股\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-01-22 23:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>1月22日，哔哩哔哩盘中涨近6%，传其港股将于三月初开始招股。</p><p>B站已于1月第二周在港正式提交了上市申请。B站上市团队希望3月在港敲钟上市，但是其具体的时间表仍需要根据港交所过聆讯的时间来安排。</p><p><img src=\"https://static.tigerbbs.com/a5f9a9adfee07fed56eed89baab74bfb\" tg-width=\"840\" tg-height=\"470\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/7c7f2e3ab9856d4cdcb423e2c4f7a729","relate_stocks":{"BILI":"哔哩哔哩"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157177739","content_text":"1月22日，哔哩哔哩盘中涨近6%，传其港股将于三月初开始招股。B站已于1月第二周在港正式提交了上市申请。B站上市团队希望3月在港敲钟上市，但是其具体的时间表仍需要根据港交所过聆讯的时间来安排。","news_type":1},"isVote":1,"tweetType":1,"viewCount":811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}